AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 20300753 — intervention group
Group type: EXPERIMENTAL
Intervention: Eritrosedimention rate (ESR)
Number of subjects: 20
Study 20300753 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogical scale score (VAS)
Number of subjects: 20
Study 20300753 — intervention group
Group type: EXPERIMENTAL
Intervention: ESR at baseline
Number of subjects: 20
Study 20300753 — intervention group
Group type: EXPERIMENTAL
Intervention: VAS difference from first to second month
Number of subjects: 20
Study 18608825 — intervention group
Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine
Number of subjects: 61
Study 18608825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 16006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine periprostatic nerve block (PPNB)
Number of subjects: 165
Study 16006882 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac suppository (DS)
Number of subjects: 165
Study 16006882 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lidocaine PPNB and DS
Number of subjects: 165
Study 12479658 — intervention group
Group type: COMPARATOR
Intervention: Mood stabilizer alone
Number of subjects: 39
Study 12479658 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant
Number of subjects: 39
Study 10342350 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound treatment (20 minutes daily for 75 days)
Number of subjects: 32
Study 10342350 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (20 minutes daily for 75 days)
Number of subjects: 32
Study 10342350 — intervention group
Group type: EXPERIMENTAL
Intervention: Active ultrasound treatment
Number of subjects: 32
Study 10342350 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 32
Study 7718317 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly 20 mg mitoxantrone intravesically for 6 weeks after TUR
Number of subjects: 126
Study 7718317 — intervention group
Group type: COMPARATOR
Intervention: No further treatment
Number of subjects: 126
Study 1940194 — intervention group
Group type: EXPERIMENTAL
Intervention: Ornoprostil
Number of subjects: 16
Study 1940194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 7185773 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazepam (tranquillizing agent)
Number of subjects: 24
Study 7185773 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 31039579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrontal tDCS (transcranial direct current stimulation) administered to the left prefrontal cortex prior to CBT for eight weekly sessions
Number of subjects: 39
Study 31039579 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefrontal tDCS in individuals with high left prefrontal cortex activation at baseline
Number of subjects: 39
Study 31039579 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 39
Study 29030644 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump training program
Number of subjects: 23
Study 29030644 — intervention group
Group type: COMPARATOR
Intervention: Control group (bed rest without intervention)
Number of subjects: 23
Study 27424295 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 15 mg
Number of subjects: 24
Study 27424295 — intervention group
Group type: EXPERIMENTAL
Intervention: Suvorexant 30 mg
Number of subjects: 24
Study 27424295 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone 7.5 mg
Number of subjects: 24
Study 27424295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23829494 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic salbutamol (200 μg q.i.d.)
Number of subjects: 30
Study 23829494 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosalbutamol (100 μg q.i.d.)
Number of subjects: 30
Study 23829494 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pelvic floor muscle exercises (PG‐PFME)
Number of subjects: 66
Study 22488800 — intervention group
Group type: COMPARATOR
Intervention: Standard pelvic floor muscle exercises (F‐PFME)
Number of subjects: 66
Study 22488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical retropubic prostatectomy (RRP)
Number of subjects: 66
Study 22488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative continence status
Number of subjects: 66
Study 22488800 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-nerve sparing approach
Number of subjects: 66
Study 19003983 — intervention group
Group type: EXPERIMENTAL
Intervention: TOP2A positivity in chemoresistant patients
Number of subjects: 148
Study 19003983 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoposide (single agent)
Number of subjects: 148
Study 17213244 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodex Stability System (one-leg stance protocol)
Number of subjects: 70
Study 15893351 — intervention group
Group type: EXPERIMENTAL
Intervention: Killed whole‐cell Leishmania amazonensis vaccine (3 doses at 20-day intervals)
Number of subjects: 2597
Study 15893351 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 doses at 20-day intervals)
Number of subjects: 2597
Study 11474721 — intervention group
Group type: EXPERIMENTAL
Intervention: Response time restriction
Number of subjects: 540
Study 11474721 — intervention group
Group type: EXPERIMENTAL
Intervention: Personality inventories
Number of subjects: 540
Study 11474721 — intervention group
Group type: EXPERIMENTAL
Intervention: Response time limitation
Number of subjects: 540
Study 9758071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine/bupivicaine local anesthetic (LA)
Number of subjects: 7
Study 9758071 — intervention group
Group type: COMPARATOR
Intervention: Saline (S)
Number of subjects: 7
Study 7511324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran-coated superparamagnetic iron oxide particles (BMS 180549) at a dose of 1.7 mg Fe/kg
Number of subjects: 5
Study 7511324 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran-coated superparamagnetic iron oxide particles (BMS 180549) at doses ranging from 0.3 to 1.7 mg Fe/kg
Number of subjects: 5
Study 3293671 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term emotional support
Number of subjects: 0
Study 3293671 — intervention group
Group type: EXPERIMENTAL
Intervention: Information-provision
Number of subjects: 0
Study 3293671 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 0
Study 30449151 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum external trigeminal nerve stimulation (CEFALY Technology) for 1 hour
Number of subjects: 106
Study 30449151 — intervention group
Group type: COMPARATOR
Intervention: Sham external trigeminal nerve stimulation
Number of subjects: 106
Study 30449151 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum external trigeminal nerve stimulation for migraine without aura
Number of subjects: 106
Study 30449151 — intervention group
Group type: COMPARATOR
Intervention: Sham external trigeminal nerve stimulation for migraine without aura
Number of subjects: 106
Study 30449151 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum external trigeminal nerve stimulation for migraine with aura
Number of subjects: 106
Study 30449151 — intervention group
Group type: COMPARATOR
Intervention: Sham external trigeminal nerve stimulation for migraine with aura
Number of subjects: 106
Study 28158524 — intervention group
Group type: EXPERIMENTAL
Intervention: Participatory trial intervention (details on dosage and duration not available)
Number of subjects: 0
Study 28158524 — intervention group
Group type: COMPARATOR
Intervention: Randomized wait-list control group design
Number of subjects: 0
Study 25582785 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine
Number of subjects: 90
Study 25582785 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Number of subjects: 90
Study 25582785 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of lidocaine and bupivacaine
Number of subjects: 90
Study 23823050 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking Compression Plate (LCP)
Number of subjects: 42
Study 23823050 — intervention group
Group type: COMPARATOR
Intervention: Dynamic Compression Plate (DCP)
Number of subjects: 42
Study 22132379 — intervention group
Group type: EXPERIMENTAL
Intervention: Small‐sided games-based exercise (45 minutes, three times per week for four weeks)
Number of subjects: 20
Study 22132379 — intervention group
Group type: COMPARATOR
Intervention: Control group (one-month gym membership after the trial)
Number of subjects: 20
Study 20183690 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Internet-delivered self-help treatment (5 weekly text modules, video exposure, Internet support)
Number of subjects: 30
Study 20183690 — intervention group
Group type: COMPARATOR
Intervention: Live-exposure treatment (1 session of 3 hours following a brief orientation)
Number of subjects: 30
Study 20183690 — intervention group
Group type: EXPERIMENTAL
Intervention: Spider phobia questionnaire
Number of subjects: 30
Study 17078096 — intervention group
Group type: EXPERIMENTAL
Intervention: p16(INK4a)
Number of subjects: 400
Study 17078096 — intervention group
Group type: EXPERIMENTAL
Intervention: HC2
Number of subjects: 400
Study 16929589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of interferon alfa-2b plus ribavirin for 48 weeks
Number of subjects: 100
Study 16929589 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy of interferon alfa-2b plus ribavirin
Number of subjects: 100
Study 11087644 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative radiotherapy (20 Gy/5 days) and intraoperative radiotherapy (20 Gy using 8-12 electrons)
Number of subjects: 78
Study 11087644 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 78
Study 11087644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment (pre-operative and intraoperative radiotherapy)
Number of subjects: 78
Study 8967308 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-fractioned heparin (Liquemine)
Number of subjects: 500
Study 8967308 — intervention group
Group type: COMPARATOR
Intervention: Low molecular weight heparin (Fraxiparine)
Number of subjects: 500
Study 14621767 — intervention group
Group type: EXPERIMENTAL
Intervention: Orthotopic liver transplantation (OLT)
Number of subjects: 28
Study 14621767 — intervention group
Group type: COMPARATOR
Intervention: Heterotopic liver transplantation (HLT)
Number of subjects: 28
Study 4083303 — intervention group
Group type: EXPERIMENTAL
Intervention: Evening dosing with Uniphyl (10 P.M.)
Number of subjects: 0
Study 4083303 — intervention group
Group type: COMPARATOR
Intervention: Morning dosing with Uniphyl (8 A.M.)
Number of subjects: 0
Study 30282639 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive CR (exercise + education)
Number of subjects: 115
Study 30282639 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-only CR
Number of subjects: 115
Study 30282639 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive CR
Number of subjects: 115
Study 30282639 — intervention group
Group type: COMPARATOR
Intervention: Control (wait-list)
Number of subjects: 115
Study 28192220 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Condition (FC) - participants received vibrotactile feedback from their fork when eating too fast (more than one bite per 10 s)
Number of subjects: 114
Study 28192220 — intervention group
Group type: COMPARATOR
Intervention: Non‐Feedback Condition (NFC)
Number of subjects: 114
Study 28192220 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback Condition (FC)
Number of subjects: 114
Study 24661917 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential-time-to-positivity (DTP) method without catheter withdrawal
Number of subjects: 52
Study 24661917 — intervention group
Group type: COMPARATOR
Intervention: Standard strategy requiring catheter withdrawal
Number of subjects: 52
Study 23534865 — intervention group
Group type: EXPERIMENTAL
Intervention: Folate-fortified oral contraceptive (OC)
Number of subjects: 385
Study 23534865 — intervention group
Group type: COMPARATOR
Intervention: Marketed oral contraceptive (OC)
Number of subjects: 385
Study 22640829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 10 mg/kg days 1 and 15; paclitaxel 90 mg/m(2) days 1, 8, and 15, every 4 weeks (Arm A)
Number of subjects: 561
Study 22640829 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab 15 mg/kg day 1; capecitabine 1000 mg/m(2) b.i.d., days 1‐14, every 3 weeks (Arm B)
Number of subjects: 561
Study 22640829 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 561
Study 19098116 — intervention group
Group type: EXPERIMENTAL
Intervention: Soccer group (SO)
Number of subjects: 36
Study 19098116 — intervention group
Group type: EXPERIMENTAL
Intervention: Running group (RU)
Number of subjects: 36
Study 19098116 — intervention group
Group type: COMPARATOR
Intervention: Control group (CO)
Number of subjects: 36
Study 17562950 — intervention group
Group type: EXPERIMENTAL
Intervention: Women with heart failure
Number of subjects: 7599
Study 17562950 — intervention group
Group type: COMPARATOR
Intervention: Men with heart failure
Number of subjects: 7599
Study 15272398 — intervention group
Group type: EXPERIMENTAL
Intervention: 23-valent polysaccharide vaccine
Number of subjects: 0
Study 12202123 — intervention group
Group type: COMPARATOR
Intervention: Serum COMP levels measured at baseline and study end
Number of subjects: 48
Study 10353371 — intervention group
Group type: COMPARATOR
Intervention: Perceptual fluency as a cue for recognition in amnesic patients (Experiment 1)
Number of subjects: 0
Study 10353371 — intervention group
Group type: COMPARATOR
Intervention: Perceptual fluency as a cue for recognition in amnesic patients (Experiment 2)
Number of subjects: 0
Study 10353371 — intervention group
Group type: COMPARATOR
Intervention: Perceptual fluency effect on judgments for studied and unstudied items (Experiment 2)
Number of subjects: 0
Study 8942331 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin
Number of subjects: 29
Study 8942331 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study 1661490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electric stimulation (TES) combined with pharmacotherapy (group I)
Number of subjects: 189
Study 1661490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electric stimulation (TES) alone (group II)
Number of subjects: 189
Study 1661490 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 189
Study 1661490 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial electric stimulation (TES)
Number of subjects: 189
Study 6762889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine (50 mg three times a day for 4 weeks)
Number of subjects: 131
Study 6762889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 6762889 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirenzepine
Number of subjects: 131
Study 4063643 — intervention group
Group type: EXPERIMENTAL
Intervention: X ray exposure of 1.0 Gy
Number of subjects: 0
Study 4063643 — intervention group
Group type: EXPERIMENTAL
Intervention: X ray exposure of 0.5 to 1.0 Gy
Number of subjects: 0
Study 29357488 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity roller massage
Number of subjects: 0
Study 29357488 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity roller massage
Number of subjects: 0
Study 29357488 — intervention group
Group type: COMPARATOR
Intervention: Sham roller massage
Number of subjects: 0
Study 26867141 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training program for 12 weeks
Number of subjects: 15
Study 25192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose helical CT scan for lung cancer screening (NLST)
Number of subjects: 294
Study 25192282 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular cancer screening (PLCO)
Number of subjects: 294
Study 25192282 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (PLCO)
Number of subjects: 294
Study 22539590 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 10 mg
Number of subjects: 326
Study 22539590 — intervention group
Group type: EXPERIMENTAL
Intervention: Taspoglutide 20 mg
Number of subjects: 326
Study 22539590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 326
Study 23437549 — intervention group
Group type: EXPERIMENTAL
Intervention: Vimang for six months
Number of subjects: 68
Study 23437549 — intervention group
Group type: COMPARATOR
Intervention: Placebo for six months
Number of subjects: 68
Study 18214519 — intervention group
Group type: EXPERIMENTAL
Intervention: Coupled eccentric-concentric contraction training for 36 weeks
Number of subjects: 0
Study 18214519 — intervention group
Group type: COMPARATOR
Intervention: Concentric-alone muscle contraction (SQJ)
Number of subjects: 0
Study 16733277 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment for giardiasis
Number of subjects: 12
Study 16733277 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 12
Study 15004985 — intervention group
Group type: EXPERIMENTAL
Intervention: Evidence-based strategies to change clinical behaviour
Number of subjects: 0
Study 15004985 — intervention group
Group type: EXPERIMENTAL
Intervention: Systematic reviews
Number of subjects: 0
Study 11020032 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of drugs taken prior to admission
Number of subjects: 183
Study 11020032 — intervention group
Group type: COMPARATOR
Intervention: Knowledge of drugs received during hospitalization
Number of subjects: 183
Study 11020032 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 183
Study 11020032 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with lower education
Number of subjects: 183
Study 11020032 — intervention group
Group type: EXPERIMENTAL
Intervention: Importance rating of drug characteristics
Number of subjects: 183
Study 11020032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sources of drug information
Number of subjects: 183
Study 9032890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipoprotein OspA vaccine
Number of subjects: 300
Study 9032890 — intervention group
Group type: EXPERIMENTAL
Intervention: Unlipidated OspA vaccine
Number of subjects: 300
Study 9032890 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidated OspA vaccine
Number of subjects: 300
Study 9032890 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 300
Study 1891755 — intervention group
Group type: EXPERIMENTAL
Intervention: TXA2 synthetase inhibitor (Cataclot) administered to 13 patients by continuous drip infusion at a dose of 1 microgram/kg/min for 8 to 14 days (group A)
Number of subjects: 24
Study 1891755 — intervention group
Group type: COMPARATOR
Intervention: Control group (11 patients, group B)
Number of subjects: 24
Study 6385722 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 120
Study 6385722 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 30366759 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based tele-rehabilitation program (n=141)
Number of subjects: 283
Study 30366759 — intervention group
Group type: COMPARATOR
Intervention: Conventional care (control group, n=142)
Number of subjects: 283
Study 28685892 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-led self-management intervention (INT, n = 232)
Number of subjects: 463
Study 28685892 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC, n = 231)
Number of subjects: 463
Study 27141951 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-breastfeeding intervention (six counseling sessions at 7, 15, 30, 60, and 120 days postpartum)
Number of subjects: 323
Study 27141951 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention details provided)
Number of subjects: 323
Study 25100438 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 59
Study 25100438 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 59
Study 22303911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 300/10 mg
Number of subjects: 847
Study 22303911 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine 150/10 mg
Number of subjects: 847
Study 22303911 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 847
Study 19914303 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (1000 mg)
Number of subjects: 8
Study 19914303 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 17516958 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous sulphate tablet (150 g tablet, containing 50 mg of elemental iron) daily throughout pregnancy
Number of subjects: 727
Study 17516958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study 16271570 — intervention group
Group type: EXPERIMENTAL
Intervention: Forced-use therapy (FUT) combined with conventional rehabilitation program
Number of subjects: 31
Study 16271570 — intervention group
Group type: COMPARATOR
Intervention: Conventional rehabilitation program only (Control)
Number of subjects: 31
Study 12140804 — intervention group
Group type: EXPERIMENTAL
Intervention: BiDil (H+ISDN)
Number of subjects: 600
Study 12140804 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 600
Study 9659093 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 ml 75% sucrose solution
Number of subjects: 107
Study 9659093 — intervention group
Group type: COMPARATOR
Intervention: Sterile water (control)
Number of subjects: 107
Study 8127992 — intervention group
Group type: EXPERIMENTAL
Intervention: 41-item La Monica-Oberst Patient Satisfaction Scale (LOPSS)
Number of subjects: 307
Study 8127992 — intervention group
Group type: EXPERIMENTAL
Intervention: 28-item revised La Monica-Oberst Patient Satisfaction Scale (LOPSS)
Number of subjects: 307
Study 2556172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 216
Study 2556172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 80 mg once daily
Number of subjects: 216
Study 2556172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 2556172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 1.25 mg once daily
Number of subjects: 216
Study 2556172 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 5 mg once daily
Number of subjects: 216